Pub Date : 2020-02-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.009
Qian Liu, Jian-hua Tang, Zhihua Zhang
Objective To systematically evaluate the relationship between CXCR4 and the clinicopathological characteristics and prognosis of patients with non-small cell lung cancer (NSCLC). Methods The PubMed, EMbase, Cochrane Library, CNKI, Wanfang and China Biology Medicine databases were searched by the computer to collect the publicly published cohort studies on the correlation between CXCR4 expression and prognosis of NSCLC. The retrieval time was from the establishment of the database to May 31, 2018. Literature screening, data extraction and risk of bias were performed independently by two reviewers, and Meta-analysis was performed by using Stata 12.0 software. Results Finally, 20 studies were included, with a total of 2 124 NSCLC patients. The positive expression rate of CXCR4 in patients with adenocarcinoma was 51.8% (337/650) and it was 50.3% (224/445) in patients with squamous cell carcinoma, the difference was statistically significant (RR=1.22, 95% CI 1.09-1.38, P=0.001). The positive expression rate of CXCR4 in patients with stageⅠ-Ⅱ was 41.1% (317/772), and the rate was 57.0% (348/610) in patients with stage Ⅲ-Ⅳ, the difference was statistically significant (RR=0.62, 95% CI 0.55-0.69, P < 0.01). The positive expression rate of CXCR4 in patients with distant metastasis was 55.3% (268/485), and the positive rate of CXCR4 in those without distant metastasis was 39.2% (256/653), the difference was statistically significant (RR=1.78, 95% CI 1.54-2.06, P < 0.01). The expression of CXCR4 was not related to the size and invasion of the primary tumor, the positive expression rates of CXCR4 in T1-T2 and T3-T4 patients were 41.0%(215/524) and 53.8%(84/156) (RR=0.71, 95% CI 0.60-0.84, P=0.053). The overall survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative, and the difference was statistically significant (30.1% vs. 66.9%, RR=0.45, 95% CI 0.30-0.61, P < 0.01). The disease-free survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative (38.0% vs. 20.1%, RR=1.89, 95% CI 1.45-2.47, P=0.002). Conclusions The pathological type, tumor staging and distant metastasis of NSCLC patients are correlated with CXCR4 expression level. The expression level of CXCR4 in tumor tissues has a predictive value for the prognosis of NSCLC patients; and the higher the expression level of CXCR4 is, the lower the overall survival and disease-free survival rates are. Key words: Carcinoma, non-small-cell lung; CXCR4; Prognosis; Meta-analysis
目的系统评价CXCR4与非小细胞肺癌(NSCLC)患者临床病理特征及预后的关系。方法计算机检索PubMed、EMbase、Cochrane Library、CNKI、万方、中国生物医学数据库，收集已公开发表的关于CXCR4表达与NSCLC预后相关性的队列研究。检索时间为数据库建立至2018年5月31日。文献筛选、数据提取及偏倚风险由2位审稿人独立完成，meta分析采用Stata 12.0软件进行。结果最终纳入20项研究，共纳入2 124例NSCLC患者。CXCR4在腺癌患者中的阳性表达率为51.8%(337/650)，在鳞状细胞癌患者中的阳性表达率为50.3%(224/445)，差异有统计学意义(RR=1.22, 95% CI 1.09 ~ 1.38, P=0.001)。Ⅰ~Ⅱ期CXCR4阳性表达率为41.1%(317/772)，Ⅲ~Ⅳ期CXCR4阳性表达率为57.0%(348/610)，差异有统计学意义(RR=0.62, 95% CI 0.55 ~ 0.69, P < 0.01)。有远处转移的患者CXCR4阳性表达率为55.3%(266 /485)，无远处转移的患者CXCR4阳性表达率为39.2%(256/653)，差异有统计学意义(RR=1.78, 95% CI 1.54 ~ 2.06, P < 0.01)。CXCR4的表达与原发肿瘤的大小和侵袭程度无关，T1-T2和T3-T4患者中CXCR4的阳性表达率分别为41.0%(215/524)和53.8%(84/156)(RR=0.71, 95% CI 0.60-0.84, P=0.053)。cxcr4阳性患者的总生存率低于cxcr4阴性患者，差异有统计学意义(30.1%比66.9%，RR=0.45, 95% CI 0.30 ~ 0.61, P < 0.01)。cxcr4阳性患者的无病生存率低于cxcr4阴性患者(38.0% vs. 20.1%， RR=1.89, 95% CI 1.45-2.47, P=0.002)。结论非小细胞肺癌患者的病理类型、肿瘤分期及远处转移与CXCR4表达水平相关。CXCR4在肿瘤组织中的表达水平对NSCLC患者的预后有预测价值;CXCR4表达水平越高，总生存率和无病生存率越低。关键词:肺癌，非小细胞肺;趋化因子受体CXCR4;预后;荟萃分析
{"title":"Correlation of CXCR4 expression with clinicopathological characteristics and prognosis of patients with non-small cell lung cancer: a Meta-analysis","authors":"Qian Liu, Jian-hua Tang, Zhihua Zhang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.009","url":null,"abstract":"Objective \u0000To systematically evaluate the relationship between CXCR4 and the clinicopathological characteristics and prognosis of patients with non-small cell lung cancer (NSCLC). \u0000 \u0000 \u0000Methods \u0000The PubMed, EMbase, Cochrane Library, CNKI, Wanfang and China Biology Medicine databases were searched by the computer to collect the publicly published cohort studies on the correlation between CXCR4 expression and prognosis of NSCLC. The retrieval time was from the establishment of the database to May 31, 2018. Literature screening, data extraction and risk of bias were performed independently by two reviewers, and Meta-analysis was performed by using Stata 12.0 software. \u0000 \u0000 \u0000Results \u0000Finally, 20 studies were included, with a total of 2 124 NSCLC patients. The positive expression rate of CXCR4 in patients with adenocarcinoma was 51.8% (337/650) and it was 50.3% (224/445) in patients with squamous cell carcinoma, the difference was statistically significant (RR=1.22, 95% CI 1.09-1.38, P=0.001). The positive expression rate of CXCR4 in patients with stageⅠ-Ⅱ was 41.1% (317/772), and the rate was 57.0% (348/610) in patients with stage Ⅲ-Ⅳ, the difference was statistically significant (RR=0.62, 95% CI 0.55-0.69, P < 0.01). The positive expression rate of CXCR4 in patients with distant metastasis was 55.3% (268/485), and the positive rate of CXCR4 in those without distant metastasis was 39.2% (256/653), the difference was statistically significant (RR=1.78, 95% CI 1.54-2.06, P < 0.01). The expression of CXCR4 was not related to the size and invasion of the primary tumor, the positive expression rates of CXCR4 in T1-T2 and T3-T4 patients were 41.0%(215/524) and 53.8%(84/156) (RR=0.71, 95% CI 0.60-0.84, P=0.053). The overall survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative, and the difference was statistically significant (30.1% vs. 66.9%, RR=0.45, 95% CI 0.30-0.61, P < 0.01). The disease-free survival rate of patients with CXCR4-positive was lower than that of patients with CXCR4-negative (38.0% vs. 20.1%, RR=1.89, 95% CI 1.45-2.47, P=0.002). \u0000 \u0000 \u0000Conclusions \u0000The pathological type, tumor staging and distant metastasis of NSCLC patients are correlated with CXCR4 expression level. The expression level of CXCR4 in tumor tissues has a predictive value for the prognosis of NSCLC patients; and the higher the expression level of CXCR4 is, the lower the overall survival and disease-free survival rates are. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; CXCR4; Prognosis; Meta-analysis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43571162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hyalinizing trabecular tumor of the thyroid: report of one case and review of literature","authors":"Jin-xiang Huang, Nong Cao","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.012","url":null,"abstract":"目的 \u0000提高对甲状腺透明变梁状肿瘤（HTT）的认识，掌握其诊断和治疗。 \u0000 \u0000 \u0000方法 \u0000回顾性分析2019年5月兰州大学第一医院收治的1例HTT患者的临床资料，并进行文献复习。 \u0000 \u0000 \u0000结果 \u0000该患者主要临床表现为颈部肿物渐进性增大、胸闷、气短等，入院行左侧甲状腺切除术，其病理及免疫组织化学证实为HTT伴微小乳头状癌。 \u0000 \u0000 \u0000结论 \u0000HTT是一种具有潜在低度恶性的甲状腺肿瘤，最大特点是具有小梁状的玻璃样变性，外科手术是主要治疗手段。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48098646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.005
J. Xing, Zhen-Yuan Yan, Bin Yang, Jinnan Gao
Objective To explore the clinical application value of sentinel lymph node biopsy (SLNB) in patients with early breast cancer after local excision surgery. Methods A total of 93 breast cancer patients with clinical stage Tis/T1-2N0M0 who underwent SLNB and were confirmed by using tumor mass excision biopsy from March 2012 to November 2018 in Shanxi Bethune Hospital were retrospectively analyzed. According to the postoperative paraffin pathology, the patients who were successfully detected sentinel lymph node (SLN) were divided into SLN-positive group with metastasis or SLN-negative group without metastasis. The clinicopathological data were used to analyze influencing factors of SLN metastasis and SLN detection number after excision biopsy of breast masses in the two groups. Results A total of 87 out of 93 patients were successfully detected SLN and the detection rate was 93.5% (87/93). A total of 255 SLN were detected, and the average number was 2.93 in per patient. All were subjected to rapid intraoperative freezing pathological, and 11 cases with positive SLN were detected. There were 17 patients who underwent axillary lymph node dissection (ALND), including 11 cases with positive SLN and 6 cases with SLN undetected. The paraffin pathology showed that 14 patients were confirmed as positive SLN, including 13 macrometastasis and 1 micrometastasis. The SLN false negative rate was 2.1% (3/14) of intraoperative frozen diagnosis. Univariate analysis showed that histological grade and intravascular thrombus of carcinoma were associated with SLN metastasis after breast cancer local excision; the number of SLN detection was effected by body mass index and staining method; the methylene staining method combined with radionuclide method could improve the detection rate of SLN (all P < 0.05). Multivariate analysis showed that the SLN non-detection of obesity patients was 2.651 times as much as that of normal patients (95% CI 1.592-8.194, P=0.010). Conclusion The SLNB and appropriate tracer method will have a high SLN detection rate and better clinical application value for early breast cancer patients after breast mass resection. Key words: Breast neoplasms; Mastectomy; Sentinel lymph node biopsy
目的探讨前哨淋巴结活检(SLNB)在早期乳腺癌局部切除术后的临床应用价值。方法回顾性分析2012年3月至2018年11月山西白求恩医院93例临床分期ti /T1-2N0M0行SLNB并经肿瘤肿块切除活检证实的乳腺癌患者。根据术后石蜡病理将成功检出前哨淋巴结(SLN)的患者分为有转移的SLN阳性组和无转移的SLN阴性组。通过临床病理资料分析两组乳腺肿块切除活检后SLN转移及SLN检测数的影响因素。结果93例患者中87例成功检出SLN，检出率为93.5%(87/93)。共检测到SLN 255个，平均2.93个/例。所有患者均行术中快速冷冻病理检查，其中11例SLN阳性。17例患者行腋窝淋巴结清扫术(ALND)，其中11例SLN阳性，6例未检出SLN。石蜡病理证实14例SLN阳性，其中大转移13例，微转移1例。术中冷冻诊断SLN假阴性率为2.1%(3/14)。单因素分析显示，乳腺癌局部切除后肿瘤的组织学分级和血管内血栓与SLN转移相关;体质指数和染色法影响SLN的检测数量;亚甲基染色法联合放射性核素法可提高SLN的检出率(P < 0.05)。多因素分析显示，肥胖患者的SLN未检出率是正常患者的2.651倍(95% CI 1.592 ~ 8.194, P=0.010)。结论SLNB及合适的示踪方法对乳腺肿块切除术后的早期乳腺癌患者具有较高的SLN检出率和较好的临床应用价值。关键词:乳腺肿瘤;乳房切除术;前哨淋巴结活检
{"title":"Clinical application of sentinel lymph node biopsy in patients with early breast cancer after local excision surgery","authors":"J. Xing, Zhen-Yuan Yan, Bin Yang, Jinnan Gao","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.005","url":null,"abstract":"Objective \u0000To explore the clinical application value of sentinel lymph node biopsy (SLNB) in patients with early breast cancer after local excision surgery. \u0000 \u0000 \u0000Methods \u0000A total of 93 breast cancer patients with clinical stage Tis/T1-2N0M0 who underwent SLNB and were confirmed by using tumor mass excision biopsy from March 2012 to November 2018 in Shanxi Bethune Hospital were retrospectively analyzed. According to the postoperative paraffin pathology, the patients who were successfully detected sentinel lymph node (SLN) were divided into SLN-positive group with metastasis or SLN-negative group without metastasis. The clinicopathological data were used to analyze influencing factors of SLN metastasis and SLN detection number after excision biopsy of breast masses in the two groups. \u0000 \u0000 \u0000Results \u0000A total of 87 out of 93 patients were successfully detected SLN and the detection rate was 93.5% (87/93). A total of 255 SLN were detected, and the average number was 2.93 in per patient. All were subjected to rapid intraoperative freezing pathological, and 11 cases with positive SLN were detected. There were 17 patients who underwent axillary lymph node dissection (ALND), including 11 cases with positive SLN and 6 cases with SLN undetected. The paraffin pathology showed that 14 patients were confirmed as positive SLN, including 13 macrometastasis and 1 micrometastasis. The SLN false negative rate was 2.1% (3/14) of intraoperative frozen diagnosis. Univariate analysis showed that histological grade and intravascular thrombus of carcinoma were associated with SLN metastasis after breast cancer local excision; the number of SLN detection was effected by body mass index and staining method; the methylene staining method combined with radionuclide method could improve the detection rate of SLN (all P < 0.05). Multivariate analysis showed that the SLN non-detection of obesity patients was 2.651 times as much as that of normal patients (95% CI 1.592-8.194, P=0.010). \u0000 \u0000 \u0000Conclusion \u0000The SLNB and appropriate tracer method will have a high SLN detection rate and better clinical application value for early breast cancer patients after breast mass resection. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Mastectomy; Sentinel lymph node biopsy","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46596041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.008
Linying Wang, Min Li, Hulin Liu, Jun Guo, Jingjing Han, Yanyan Gao
Objective To investigate the correlation between mental health and symptom distress in breast cancer patients. Methods The clinical data of 110 female breast cancer patients at Shanxi Bethune Hospital from June 2017 to March 2018 were collected. The patients were assessed for symptomatic distress with depression self-rating scale (SDS). Functional assessment of cancer therapy-breast (FACT-B) and the functional assessment of chronic illness therapy-spiritual well-being (FACIT-SP) were used to make the mental assessment. Multiple linear regression analysis was used to analyze the effect of symptom distress on the mental health of the patients. Results The scores of symptom distress, mental health, FACT-B and FACIT-SP were (19.94±5.78), (50.68±10.64), (16.85±4.75), (33.83±8.33), respectively. Multivariate analysis showed that mental health score of the patients with symptom distress > 18 scores was reduced by 5.15 points (P=0.01) compared with the patients with symptom distress≤18 scores. Compared with the patients with annual household income < 50 000 yuan, the mental health score of patients with annual household income of 50 000-79 000 yuan was increased by 9.46 points (P < 0.01), and the mental health score of patients with annual family income ≥ 80 000 yuan was increased by 5.92 points (P < 0.01); compared with the patients in phase I, the mental health score of the patients in phaseⅡwas decreased by 2.62 points (P=0.02), and the mental health score of the patients in phase Ⅲ was decreased by 4.98 points (P < 0.01). Conclusions Symptom distress is an independent risk factor for affecting mental health of breast cancer patients. Solving symptom distress of patients can improve mental health status of the patients. Key words: Breast neoplasms; Mental health; Symptom distress
{"title":"Correlation analysis between mental health and symptom distress in breast cancer patients","authors":"Linying Wang, Min Li, Hulin Liu, Jun Guo, Jingjing Han, Yanyan Gao","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.008","url":null,"abstract":"Objective \u0000To investigate the correlation between mental health and symptom distress in breast cancer patients. \u0000 \u0000 \u0000Methods \u0000The clinical data of 110 female breast cancer patients at Shanxi Bethune Hospital from June 2017 to March 2018 were collected. The patients were assessed for symptomatic distress with depression self-rating scale (SDS). Functional assessment of cancer therapy-breast (FACT-B) and the functional assessment of chronic illness therapy-spiritual well-being (FACIT-SP) were used to make the mental assessment. Multiple linear regression analysis was used to analyze the effect of symptom distress on the mental health of the patients. \u0000 \u0000 \u0000Results \u0000The scores of symptom distress, mental health, FACT-B and FACIT-SP were (19.94±5.78), (50.68±10.64), (16.85±4.75), (33.83±8.33), respectively. Multivariate analysis showed that mental health score of the patients with symptom distress > 18 scores was reduced by 5.15 points (P=0.01) compared with the patients with symptom distress≤18 scores. Compared with the patients with annual household income < 50 000 yuan, the mental health score of patients with annual household income of 50 000-79 000 yuan was increased by 9.46 points (P < 0.01), and the mental health score of patients with annual family income ≥ 80 000 yuan was increased by 5.92 points (P < 0.01); compared with the patients in phase I, the mental health score of the patients in phaseⅡwas decreased by 2.62 points (P=0.02), and the mental health score of the patients in phase Ⅲ was decreased by 4.98 points (P < 0.01). \u0000 \u0000 \u0000Conclusions \u0000Symptom distress is an independent risk factor for affecting mental health of breast cancer patients. Solving symptom distress of patients can improve mental health status of the patients. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Mental health; Symptom distress","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45246364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To detect the infection and subtype status of human papilloma virus (HPV) for patients with head and neck squamous cell carcinoma (HNSCC) treated in a single center in Chaoshan area of Guangdong Province. Methods The primary lesion samples from 167 HNSCC patients in Cancer Hospital of Shantou University Medical College between December 2014 and December 2016 were collected. The expression of p16 protein in tumor tissues was detected by using immunohistochemistry (IHC), and the positive rate of tumor cell p16 protein≥ 76% was used as a diagnostic standard to judge HPV in HNSCC; the relationship between p16 protein and the clinicopathological factors was analyzed. The status of HPV 16/18 DNA in tumor tissues was tested by using in situ hybridization(ISH). RNA scope was used to detect the RNA expression of 18 kinds of common high-risk HPV subtype (HPV HR 18), and the positive status of HPV HR 18 in tumor tissues with the positive cell proportion ≥ 50% of p16 protein was analyzed. Results The strong expression rate of p16 protein was 7.2% (12/167). The strong expression rate of p16 protein in the younger group ( 0.05). HPV 16/18 DNA was not found in all HNSCC primary lesions by using ISH, which showed the same result after repeated examination. RNAscope method showed that 3 cases (15.8%) out of the 19 patients with p16 protein positive rate≥50% were HPV HR 18 RNA positive. Conclusions The positive rate of HPV for HNSCC patients in Chaoshan area is low, while the patients with oropharyngeal carcinoma have the highest rate and tend to be younger. The main carcinogenic viruses of HPV for HNSCC patients in Chaoshan area are other subtypes of HPV including HPV HR 18 rather than HPV 16/18. Key words: Head and neck neoplasms; Carcinoma, squamous cell; Human papillomavirus; Chaoshan area
{"title":"Initial analysis of human papilloma virus for patients with head and neck squamous cell carcinoma in a single center in Chaoshan area of Guangdong Province","authors":"C.-Q. Hong, Xiaolong Wei, Muyuan Liu, Haipeng Guo, Yun Zeng, Hanwei Peng","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.004","url":null,"abstract":"Objective \u0000To detect the infection and subtype status of human papilloma virus (HPV) for patients with head and neck squamous cell carcinoma (HNSCC) treated in a single center in Chaoshan area of Guangdong Province. \u0000 \u0000 \u0000Methods \u0000The primary lesion samples from 167 HNSCC patients in Cancer Hospital of Shantou University Medical College between December 2014 and December 2016 were collected. The expression of p16 protein in tumor tissues was detected by using immunohistochemistry (IHC), and the positive rate of tumor cell p16 protein≥ 76% was used as a diagnostic standard to judge HPV in HNSCC; the relationship between p16 protein and the clinicopathological factors was analyzed. The status of HPV 16/18 DNA in tumor tissues was tested by using in situ hybridization(ISH). RNA scope was used to detect the RNA expression of 18 kinds of common high-risk HPV subtype (HPV HR 18), and the positive status of HPV HR 18 in tumor tissues with the positive cell proportion ≥ 50% of p16 protein was analyzed. \u0000 \u0000 \u0000Results \u0000The strong expression rate of p16 protein was 7.2% (12/167). The strong expression rate of p16 protein in the younger group ( 0.05). HPV 16/18 DNA was not found in all HNSCC primary lesions by using ISH, which showed the same result after repeated examination. RNAscope method showed that 3 cases (15.8%) out of the 19 patients with p16 protein positive rate≥50% were HPV HR 18 RNA positive. \u0000 \u0000 \u0000Conclusions \u0000The positive rate of HPV for HNSCC patients in Chaoshan area is low, while the patients with oropharyngeal carcinoma have the highest rate and tend to be younger. The main carcinogenic viruses of HPV for HNSCC patients in Chaoshan area are other subtypes of HPV including HPV HR 18 rather than HPV 16/18. \u0000 \u0000 \u0000Key words: \u0000Head and neck neoplasms; Carcinoma, squamous cell; Human papillomavirus; Chaoshan area","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49657670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.015
Jialing Liu, Linsheng Huang, Xin-hai Ye, Jie Zhou, Fei Li
bcl-2 inhibitor of transcription 1 (Bit1) is an anoikis effector that can play a role of caspase-independent apoptosis by down-regulating bcl-2 expression. Previous studies have found that Bit1 affects cell survival and apoptosis through Erk and FAK-PI3K-Akt-NF-κB pathways. It is worth noting that the expression of Bit1 has shown the obvious tumor specificity in different tumors, and it is closely related to TNM stage, differentiation and prognosis of the tumor. This review summarizes the expression, main mechanism, and significance of Bit1 in different tumors. Key words: Apoptosis; Neoplasms; Bcl-2 inhibitor of transcription 1
{"title":"Progress of the anoikis effector bcl-2 inhibitor of transcription 1","authors":"Jialing Liu, Linsheng Huang, Xin-hai Ye, Jie Zhou, Fei Li","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.015","url":null,"abstract":"bcl-2 inhibitor of transcription 1 (Bit1) is an anoikis effector that can play a role of caspase-independent apoptosis by down-regulating bcl-2 expression. Previous studies have found that Bit1 affects cell survival and apoptosis through Erk and FAK-PI3K-Akt-NF-κB pathways. It is worth noting that the expression of Bit1 has shown the obvious tumor specificity in different tumors, and it is closely related to TNM stage, differentiation and prognosis of the tumor. This review summarizes the expression, main mechanism, and significance of Bit1 in different tumors. \u0000 \u0000 \u0000Key words: \u0000Apoptosis; Neoplasms; Bcl-2 inhibitor of transcription 1","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43128121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.007
Tiantian Zhao
Objective To explore the relationship between gene amplification status of human epidermal growth factor receptor 2 (HER2) and its clinicopathological features in breast cancer, and to analyze the affecting factors of axillary lymph node metastasis in breast cancer. Methods The clinicopathological data of 262 patients with breast cancer at Tengzhou Central People's Hospital between January 2016 and March 2019 were collected, including age, tumor diameter, histological grade, pathological type, lymph node metastasis, tumor number, tumor location. The patients had routine pathology examination and the immunohistochemistry (IHC) result of HER2 was ++. The expressions of p53, Ki-67, estrogen receptor (ER), progesterone receptor (PR) were detected by using IHC. The gene amplification status of HER2 was detected by using fluorescence in situ hybridization (FISH). The relationship between gene amplification status of HER2 and clinicopathological features, the relationship between axillary lymph node metastasis and clinicopathological features was respectively analyzed. Results HER2 gene amplification-positive was detected in 69 cases of 262 breast cancer patients, and the positive amplification rate was 26.3%. The gene amplification status of HER2 was correlated with Ki-67 proliferation index and the expression of ER as well as PR, and the differences were statistically significant (χ 2=13.27, P 0.05). Among 262 cases of breast cancer, 106 (40.5%) cases had axillary lymph node metastasis. Lymph node metastasis was correlated with tumor diameter (χ 2=29.10, P 0.05). Conclusions HER2 gene amplification of breast cancer is associated with Ki-67 proliferation index, the expression of ER and PR. The tumor diameter is a factor for affecting axillary lymph node metastasis. Accurate judgment of the above indicators can better guide the treatment and evaluate the prognosis of breast cancer. Key words: Breast neoplasms; Human epidermal growth factor receptor 2; Gene amplification; Lymph node metastasis; Pathology, clinical
{"title":"Relationship between gene amplification status of human epidermal growth factor receptor 2 and clinicopathological features in breast cancer","authors":"Tiantian Zhao","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.007","url":null,"abstract":"Objective \u0000To explore the relationship between gene amplification status of human epidermal growth factor receptor 2 (HER2) and its clinicopathological features in breast cancer, and to analyze the affecting factors of axillary lymph node metastasis in breast cancer. \u0000 \u0000 \u0000Methods \u0000The clinicopathological data of 262 patients with breast cancer at Tengzhou Central People's Hospital between January 2016 and March 2019 were collected, including age, tumor diameter, histological grade, pathological type, lymph node metastasis, tumor number, tumor location. The patients had routine pathology examination and the immunohistochemistry (IHC) result of HER2 was ++. The expressions of p53, Ki-67, estrogen receptor (ER), progesterone receptor (PR) were detected by using IHC. The gene amplification status of HER2 was detected by using fluorescence in situ hybridization (FISH). The relationship between gene amplification status of HER2 and clinicopathological features, the relationship between axillary lymph node metastasis and clinicopathological features was respectively analyzed. \u0000 \u0000 \u0000Results \u0000HER2 gene amplification-positive was detected in 69 cases of 262 breast cancer patients, and the positive amplification rate was 26.3%. The gene amplification status of HER2 was correlated with Ki-67 proliferation index and the expression of ER as well as PR, and the differences were statistically significant (χ 2=13.27, P 0.05). Among 262 cases of breast cancer, 106 (40.5%) cases had axillary lymph node metastasis. Lymph node metastasis was correlated with tumor diameter (χ 2=29.10, P 0.05). \u0000 \u0000 \u0000Conclusions \u0000HER2 gene amplification of breast cancer is associated with Ki-67 proliferation index, the expression of ER and PR. The tumor diameter is a factor for affecting axillary lymph node metastasis. Accurate judgment of the above indicators can better guide the treatment and evaluate the prognosis of breast cancer. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Human epidermal growth factor receptor 2; Gene amplification; Lymph node metastasis; Pathology, clinical","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43304801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.014
Qingtao Ni, Chi Pan
Breast cancer is one of the most common malignant tumors in women and the second leading cause of death in female cancer patients. In recent years, the incidence of breast cancer has been increasing in China year by year, and the age of breast cancer patients becomes younger and younger. The pathogenesis of breast cancer is complex and related to many factors, such as age, family history and genetic variation. With the development of epigenetics, DNA modification plays an important role in the occurrence and development of breast cancer. This article reviews the research of DNA methylation and hydroxymethylation in breast cancer. Key words: Breast neoplasms; DNA methylation; Hydroxymethylation; Molecular biology
{"title":"Progress of DNA methylation and hydroxymethylation in breast cancer","authors":"Qingtao Ni, Chi Pan","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.014","url":null,"abstract":"Breast cancer is one of the most common malignant tumors in women and the second leading cause of death in female cancer patients. In recent years, the incidence of breast cancer has been increasing in China year by year, and the age of breast cancer patients becomes younger and younger. The pathogenesis of breast cancer is complex and related to many factors, such as age, family history and genetic variation. With the development of epigenetics, DNA modification plays an important role in the occurrence and development of breast cancer. This article reviews the research of DNA methylation and hydroxymethylation in breast cancer. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; DNA methylation; Hydroxymethylation; Molecular biology","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47331744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Urinary malignancy is a disease with high morbidity and mortality. Early detection, diagnosis, treatment response and prognosis can significantly improve patients' quality of life. The development of non-invasive liquid biopsy represents a major innovation in the field of precision medicine, opening up a new era for precision medicine and individualized treatment of cancer. Circulating biomarkers have shown a great potential utility in the diagnosis, treatment response, and prognosis of urinary tumors. This paper reviews the recent progress of liquid biopsy in urinary neoplasms. Key words: Urologic neoplasms; Prostate neoplasms; Tumor cells, circulation; Liquid biopsy; Exosomes
{"title":"Progress of liquid biopsy in urinary neoplams","authors":"Xiong Bobo, Jinsong Zhang, Ning-Li Li, Haifeng Wang, Yi-gang Zuo","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.017","url":null,"abstract":"Urinary malignancy is a disease with high morbidity and mortality. Early detection, diagnosis, treatment response and prognosis can significantly improve patients' quality of life. The development of non-invasive liquid biopsy represents a major innovation in the field of precision medicine, opening up a new era for precision medicine and individualized treatment of cancer. Circulating biomarkers have shown a great potential utility in the diagnosis, treatment response, and prognosis of urinary tumors. This paper reviews the recent progress of liquid biopsy in urinary neoplasms. \u0000 \u0000 \u0000Key words: \u0000Urologic neoplasms; Prostate neoplasms; Tumor cells, circulation; Liquid biopsy; Exosomes","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42275812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.006
Na Jing, Yu Wang
Objective To investigate the expression of epithelial-cadherin (E-cad) in triple negative breast cancer (TNBC) and its effect on the prognosis of TNBC. Methods The data of 242 female patients with TNBC in Shanxi Provincial Cancer Hospital from April 2009 to April 2012 were collected. Immunohistochemical staining was used to detect the expression of E-cad. Kaplan-Meier method and Cox proportional hazard regression model were conducted to analyze the effect of E-cad on the prognosis of TNBC patients. Results The low expression rate of E-cad in TNBC patients was 59.5% (144/242) and its expression was related to clinical TNM stage and lymph node metastasis (both P < 0.05). The median overall survival time of 242 patients was 70.7 months (7.2-95.9 months), and 50 (20.7%) patients died. The 3-year and 5-year disease-free survival (DFS) rate was 81.5% and 78.1%, and the overall survival (OS) rate was 86.5% and 81.1%, respectively. The DFS and OS rate in the E-cad low expression group were lower than those in the E-cad high expression group, and the difference was statistically significant (both P < 0.01). Cox regression model demonstrated that E-cad was an independent prognostic factor of DFS and OS (HR=0.144, 95% CI 0.057-0.365, P < 0.01; HR=0.196, 95% CI 0.073-0.710, P < 0.01). Conclusion The low expression of E-cad is correlated with metastasis and the poor prognosis of TNBC, which could be an independent prognostic factor for TNBC patients. Key words: Cadherins; Breast neoplasms; Triple negative; Prognosis
{"title":"Expression of epithelial-cadherin in triple negative breast cancer and its prognostic significance","authors":"Na Jing, Yu Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.006","url":null,"abstract":"Objective \u0000To investigate the expression of epithelial-cadherin (E-cad) in triple negative breast cancer (TNBC) and its effect on the prognosis of TNBC. \u0000 \u0000 \u0000Methods \u0000The data of 242 female patients with TNBC in Shanxi Provincial Cancer Hospital from April 2009 to April 2012 were collected. Immunohistochemical staining was used to detect the expression of E-cad. Kaplan-Meier method and Cox proportional hazard regression model were conducted to analyze the effect of E-cad on the prognosis of TNBC patients. \u0000 \u0000 \u0000Results \u0000The low expression rate of E-cad in TNBC patients was 59.5% (144/242) and its expression was related to clinical TNM stage and lymph node metastasis (both P < 0.05). The median overall survival time of 242 patients was 70.7 months (7.2-95.9 months), and 50 (20.7%) patients died. The 3-year and 5-year disease-free survival (DFS) rate was 81.5% and 78.1%, and the overall survival (OS) rate was 86.5% and 81.1%, respectively. The DFS and OS rate in the E-cad low expression group were lower than those in the E-cad high expression group, and the difference was statistically significant (both P < 0.01). Cox regression model demonstrated that E-cad was an independent prognostic factor of DFS and OS (HR=0.144, 95% CI 0.057-0.365, P < 0.01; HR=0.196, 95% CI 0.073-0.710, P < 0.01). \u0000 \u0000 \u0000Conclusion \u0000The low expression of E-cad is correlated with metastasis and the poor prognosis of TNBC, which could be an independent prognostic factor for TNBC patients. \u0000 \u0000 \u0000Key words: \u0000Cadherins; Breast neoplasms; Triple negative; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46212966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：